Edison Oncology lead programs
Orotecan®
Novel oral formulation of irinotecan
pediatric and adult malignancies
Human clinical safety and PK established
| Pre-clinical | Phase 1-2 clinical trials | Pivotal registration-directed clinical trials |
FDA Marketing Approval |
|---|---|---|---|
|
Pre-clinical Phase complete
|
Phase 1-2 clinical trials Phase in progress
|
Pivotal registration-directed clinical trials Phase not started
|
FDA Marketing Approval Phase not started
|
EO3001
mitochondrial targeting agent
clear cell ovarian cancer & solid tumors
Human clinical safety and PK established
| Pre-clinical | Phase 1-2 clinical trials | Pivotal registration-directed clinical trials |
FDA Marketing Approval |
|---|---|---|---|
|
Pre-clinical Phase complete
|
Phase 1-2 clinical trials Phase in progress
|
Pivotal registration-directed clinical trials Phase not started
|
FDA Marketing Approval Phase not started
|
Edison Oncology partnered programs
EO1001
panErbB inhibitor
solid tumors
| Pre-clinical | Phase 1-2 clinical trials | Pivotal registration-directed clinical trials |
FDA Marketing Approval |
|---|---|---|---|
|
Pre-clinical Phase complete
|
Phase 1-2 clinical trials Phase in progress
|
Pivotal registration-directed clinical trials Phase not started
|
FDA Marketing Approval Phase not started
|
solid tumors
| Pre-clinical | Phase 1-2 clinical trials | Pivotal registration-directed clinical trials |
FDA Marketing Approval |
|---|---|---|---|
|
Pre-clinical Phase in progress
|
Phase 1-2 clinical trials Phase not started
|
Pivotal registration-directed clinical trials Phase not started
|
FDA Marketing Approval Phase not started
|
Our Pipeline – Lead Programs
Orotecan®:
Orotecan is a novel, patented oral formulation of irinotecan, a major cancer therapy. Orotecan has been developed in collaboration with leading cancer clinicians to improve tolerability and patient compliance in the treatment of rare childhood tumors, with an opportunity to expand into major adult cancers.
Learn More About Orotecan Clinical Trials
EO3001 - mitochondrial targeting agent
EO3001 was studied in prior clinical trials involving more than 1,000 cancer patients. We have identified biomarker-circumscribed orphan cancer population that we believe will benefit from treatment with EO3001. Edison Oncology has filed new patents related to these discoveries.
Learn More About EO3001 Clinical Trials
Our Pipeline – Partnered Programs
EO1001
EO1001 is partnered with Apollomics Inc. EO1001 is a novel, irreversible pan-erbB inhibitor with excellent brain penetration offering the potential for improved efficacy for non-small cell lung cancer (NSCLC) and breast cancer patients with treatment-resistant disease, including brain metastasis. Edison Oncology has initiated the regulatory filing process and plans to initiate human clinical trials with EO1001 during 2021
Learn More About EO1001 Clinical Trials
Learn more about our collaborations and partnerships
DNA-damage repair inhibitors
Edison Oncology has a significant minority interest in Rakovina Therapeutics Inc. (TSX-V: RKV), a company focused on the development of new cancer treatments based on novel DNA-damage response technologies. Edison Oncology has assigned rights to its pre-clinical EO2000 series of novel of poly(ADP-ribose) polymerase (PARP) inhibitors to Rakovina Therapeutics.